{
    "nct_id": "NCT05450692",
    "official_title": "A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY",
    "inclusion_criteria": "* Histologically or cytologically documented NSCLC that is locally advanced or metastatic according to Version 8 of the IASLC Staging Manual in Thoracic Oncology.\n* Documented epidermal growth receptor factor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type status as determined at a local laboratory.\n* Documented radiological PD whilst on or after receiving the most recent treatment regimen.\n* Eligible for second- or third-line therapy and must have received an anti-PD-(L)1 therapy and a platinum doublet containing therapy for locally advanced or metastatic NSCLC either separately or in combination.\n* Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status of 0 or 1.\n* Adequate organ function and marrow reserve\n* Minimum life expectancy of 12 weeks.\n* Body weight > 30 kg and no cancer-associated cachexia.\n* Negative pregnancy test (serum test) for women of childbearing potential (WOCBP).\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 130 Years",
    "exclusion_criteria": "* Participant with mixed SCLC and NSCLC histology.\n* History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention.\n* Persistent toxicities (CTCAE Grade > 2) caused by previous anticancer therapy.\n* Active or prior documented autoimmune or inflammatory disorders.\n* Participants who have received more than one line of prior anti-PD-(L)1, either alone or in any combination.\n* Participants:\n\n  1. Must not have experienced a toxicity that led to permanent discontinuation of the prior anti-PD(L)1 therapy.\n  2. All AEs while receiving prior anti-PD(L)1 therapy must have completely resolved.\n  3. Must not have experienced a Grade ≥ 3 immune-mediated adverse event (imAE) or an immune-related neurologic or ocular AE of any grade while receiving prior anti-PD(L)1 therapy.\n  4. Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of > 10 mg prednisone or equivalent per day.\n* Participants who have received more than one prior line of platinum-based chemotherapy in metastatic setting.\n* Participants who have received a prior ataxia telangiectasia and Rad3-related protein (ATR) inhibitor.",
    "miscellaneous_criteria": ""
}